biostudies-literatureMlecnik BMEXTJapan Agency for Medical Research and DevelopmentHalioDxSociety for Immunotherapy of Cancer4346https://www.ebi.ac.uk/biostudies/studies/S-EPMC9497086biostudies-literatureUnknown14(18)<h4>Background</h4>In this study, we evaluated the prognostic value of Immunoscore in patients with stage I-III colon cancer (CC) in the Asian population. These patients were originally included in an international study led by the Society for Immunotherapy of Cancer (SITC) on 2681 patients with AJCC/UICC-TNM stages I-III CC.<h4>Methods</h4>CD3+ and cytotoxic CD8+ T-lymphocyte densities were quantified in the tumor and invasive margin by digital pathology. The association of Immunoscore with prognosis was evaluated for time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS).<h4>Results</h4>Immunoscore stratified Asian patients (n = 423) into different risk categories and was not impacted by age. Recurrence-free rates at 3 years were 78.5%, 85.2%, and 98.3% for a LoCancersClinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study.PMC9497086UMRS1138Grants-in-aid for Scientific Research-SP-directZhang GMasucci GVGrizzi FMusina AMJouret-Mourin AOhashi PSMarincola FMHazama SWang JPatel PDundr PKirilovsky AKawakami YMaby PFuruhata TFox BAHirohashi YSkalova HTaniguchi HLee JJKnijn NPages FBerger MDvan Lent-van Vliet SWang YHafezi-Bakhtiari SHijazi ATatangelo FMerkel SBerger AXu MRau TTKonopasek BCiliberto GWouters BGZlobec IAscierto PANguyen LTPaustian CMlecnik BBavi PMarliot FNagano HTorigoe TAndersson EScripcariu DVVan den Eynde MButtard BYoshino TRajvik KNDijkstra JBindea GEl Sissy CBallesteros-Merino CKolwelter JLeonard DSuzuki NKartheuser ABifulco CLafontaine LVan de Water CVocka MSpacek JHan SGeppert CINagtegaal IDPandya SJDelrio PMajdi ABotti GOkuno KVora HLugli AGrutzmann RRemue CMacGregor HLPatel JBShukla SNNemejcova KLaghi LFujita THartmann AFredriksen TMaio MZavadova ETakemasa IVink-Borger EShah BLagorce CRoehrl MHAGalon JPopivanova BPetruzelka LfalseClinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study.<h4>Background</h4>In this study, we evaluated the prognostic value of Immunoscore in patients with stage I-III colon cancer (CC) in the Asian population. These patients were originally included in an international study led by the Society for Immunotherapy of Cancer (SITC) on 2681 patients with AJCC/UICC-TNM stages I-III CC.<h4>Methods</h4>CD3+ and cytotoxic CD8+ T-lymphocyte densities were quantified in the tumor and invasive margin by digital pathology. The association of Immunoscore with prognosis was evaluated for time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS).<h4>Results</h4>Immunoscore stratified Asian patients (n = 423) into different risk categories and was not impacted by age. Recurrence-free rates at 3 years were 78.5%, 85.2%, and 98.3% for a Lo2022-01-01T00:00:00Z2022 Sep2025-04-21T16:13:15.122Z2025-02-19T00:42:05.866ZS-EPMC94970863613950610.3390/cancers14184346